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The use of oncolytic viruses has received considerable attention in recent years and many viruses have proved to be effective against
a variety of cancer models and a few are currently being used in clinical trials. However, the possible emergence and outcome of
virus-resistant tumour cells has not been addressed. We previously reported the effective use of reovirus against lymphoid
malignancies, including the Burkitt’s lymphoma cell line Raji. Here we isolated in vitro persistently infected (PI) Raji cells, and cells
‘cured’ of persistent reovirus infection (‘cured’ cells). Both PI and cured Raji cells resisted reovirus infection and cell killing in vitro. In
vivo, the PI cells were non-tumorigenic in SCID mice, but cured cells regained the parental cells’ ability to form tumours. Tumour
xenografts from the cured cells, however, were highly susceptible to reovirus oncolysis in vivo. This susceptibility was due to the
proteolytic environment within tumours that facilitates reovirus infection and cell killing. Our results show that persistent infection by
reovirus impedes tumour development and that although PI cells cleared of reovirus are tumorigenic, they are killed upon rechallenge
with reovirus. Both the PI and cured states are therefore not likely to be significant barriers to reovirus oncolytic therapy.
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Reovirus is the prototype of the Reoviridae family of double-
stranded RNA viruses that is found ubiquitously in the environ-
ment. Although most humans have been infected with this virus,
there is little or no manifestation of clinical symptoms (Tyler and
Fields, 1996). The virus is not linked to any known human diseases
and is therefore considered to be benign. More recently however,
reovirus has been shown to be an effective oncolytic agent against
a variety of cancers (Wilcox et al, 2001; Hirasawa et al, 2002;
Norman et al, 2002; Etoh et al, 2003; Kilani et al, 2003) including
lymphomas (Alain et al, 2002). These studies led to clinical trials of
reovirus as a cancer therapeutic (Morris et al, 2002).
While the use of viruses as oncolytic agents has shown
considerable promise in preclinical studies (Kirn, 2002; Bell et al,
2003), the possibility of generating or selecting for cancer cells that
have become resistant to reovirus has not been evaluated. It is
possible that a subpopulation of cancer cells may survive the initial
viral assault and become persistently infected (PI) with the virus.
Although it is not known if such residual cancer cells actually exist
in vivo, the fact that cells PI with reovirus can be established
in vitro (Taber et al, 1976; Ahmed et al, 1981; Ahmed and Fields,
1982; Danis et al, 1993; Dermody et al, 1993, 1995; Dermody, 1998)
suggests that this could be a potential problem in vivo.I ti s
therefore important to evaluate the tumorigenicity of such PI cells
relative to that of the parental cells to see if this could represent a
mechanism for proliferating tumour cells to escape initial viral
oncolysis.
Another more important concern pertains to the potential
generation, from the PI cells, of cells ‘cured’ of viral infection. In
the case of reovirus, cured cells can be generated from PI murine L
cells simply by incubation with anti-reovirus antibodies. Impor-
tantly, these cells then lack permissiveness to wild-type reovirus in
vitro (Ahmed et al, 1981; Dermody et al, 1993; Baer and Dermody,
1997; Wetzel et al, 1997; Baer et al, 1999). Whereas the presence of
viruses in PI cells may keep tumour cells in check, cured cells
without such a deterrent could potentially develop into tumours. If
cured tumours are now resistant to the original wild-type virus,
this may pose another potential therapeutic challenge.
In this study, we addressed these issues using the Burkitt’s
lymphoma cell line Raji, which we have found to be highly
susceptible to reovirus oncolysis (Alain et al, 2002). Despite this
exquisite susceptibility in vitro, we isolated a resistant population
that was PI, and generated cured cells from this PI population
using anti-reovirus antibodies. We compared the PI and cured
cells to the parental cells in terms of tumorigenicity and
susceptibility to reovirus oncolysis in vitro and in vivo. We found
that PI Raji cells were nontumorigenic, but cured cells formed
large tumours in vivo. Raji cured cells were resistant to reovirus
infection in vitro, but were highly susceptible to reovirus oncolysis
in vivo. Subsequent experiments demonstrated that the presence
of proteases within the microenvironment of Raji cured tumours
enhanced the processing and hence the oncolytic activity of
reovirus in vivo. In view of the lack of tumorigenicity of the PI cells Revised 11 August 2006; accepted 17 August 2006
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conclude that these conditions should not represent a significant
barrier for reovirus oncolytic therapy.
MATERIALS AND METHODS
Cells and reovirus
The human Burkitt’s lymphoma cell line Raji, obtained from
American Type Culture Collection (ATCC), was maintained in
RPMI containing 10% foetal bovine serum (FBS), 1% L-glutamine
(Gibco/BRL, Burlington, ON, Canada) and antibiotics (Sigma-
Aldrich, St Louis, MO, USA). Cells were kept at 371Ci na
humidified 5% CO2 incubator. For the growth curve assay, Trypan
Blue exclusion test was performed every 24h. The cells were
stained with 0.25% dye and viable cells in three independent wells
were counted using a haemocytometer.
The PI cells were established after infection of the parental Raji
cells with reovirus type 3 Dearing and isolating the surviving
populations. The surviving cells were subsequently re-infected
three times a week for 3 weeks at 20 plaque-forming units (PFU)
per cell to eliminate all cells susceptible to lysis. The cells then
underwent two periods of crisis in which the majority of cells died,
but resistant cells eventually emerged and remained PI (Raji PI).
Raji cured cells were generated by culturing the PI cells in the
presence of 1% (v/v) filter sterilised polyclonal rabbit anti-reovirus
serotype 3 antiserum. Cells were passaged in the presence of
antiserum every second day for a period of 2 weeks. The cell
population obtained following this treatment contained no
detectable viral particles.
The Dearing strain of reovirus serotype 3 was propagated in
L929 cells grown in suspension in Joklik’s modified Eagle’s
medium (JMEM) containing 5% FBS. The virus was purified
according to the protocol of Smith et al (1969), with the exception
that b-mercaptoethanol was omitted from the extraction buffer.
Infectious subviral particles (ISVPs) were obtained by digesting
virions (1 10
11PFUml
 1) with N-a-r-tosyl-i-lysine chloromethyl
ketone (TLCK)-treated a-chymotrypsin (200mgml
 1) (Sigma-
Aldrich) for 30min at 371C. Digestion was stopped by the addition
of ethanolic phenymethysulphonyl fluoride (5mM) (Sigma-Al-
drich) at 41C, and the ISVPs generated were used immediately for
cell infection.
Polymerase chain reaction and immunofluorescence
Cells were harvested and RNA was extracted using the RNeasy
protocol (Qiagen Inc., Missassauga, ON, Canada). Equal amounts
of total cellular RNA from each sample were then subjected to
RT–PCR as described previously (Strong et al, 1998). S1 cDNA
primers: 50-AATTCGAATTAGGTGACACTATAG-CTATTGGTCG
GATG-30 and 50-CCCTTTTGACAGTGATGCTCCGTTATCACTCG-
30. S2 cDNA primers: 50-TTCGCTGGTCAGTTATGGCTC-30 and
50-TACCAGCTCGGAGTAGATGTG-30.
For immunofluorescent studies, cells were spread and fixed on
slides using Cytology Fixative (Surgipath, Richmond, IL, USA).
After rehydration by sequential washes in 75, 50 and 25% ethanol
followed by four washes with phosphate-buffered saline (PBS), the
fixed and rehydrated cells were treated with 10% goat serum in
PBS and then exposed to the primary antibody (rabbit polyclonal
anti-reovirus type 3 serum diluted 1/5000 in PBS) overnight at 41C.
Following three washes with PBS, the cells were exposed to the
secondary antibody (fluorescein isothiocyanate (FITC)-conjugated
goat anti-rabbit IgG diluted 1/100 in PBS) for 1h at room
temperature. The slides were then washed three times with PBS,
mounted with DAPI mounting medium (Vector Laboratories,
Burlingame, CA, USA), and the cells were viewed and photo-
graphed with a Zeiss microscope (magnification  400).
Ras activation assays and Western blot analysis
Ras-GTP levels were measured using a Ras activation assay kit
(Upstate Biotechnology, Lake Placid, NY, USA). Subconfluent cells
in 15-cm dishes were washed two times in ice-cold TBS and
lysed by scraping in 500mlo fM g
2þ lysis buffer (MLB, Upstate
Biotechnology). Six hundred microlitres of precleared lysate was
then incubated with 30ml of GST–Raf Ras-binding domain bound
to glutathione agarose for 45min at 41C. Beads were then washed
three times in MLB and boiled in 40mlo f2 protein sample buffer
with 2ml of 1M DTT. Twenty microlitres of pull-down sample and
40ml of total lysate were then subjected to 10% SDS–PAGE and
transferred to nitrocellulose membrane. Blots were probed over-
night with 1000-fold diluted RAS10 mAb (Upstate Biotechnology)
and then washed three times for 5min in TBS/0.1% Tween-20,
followed by incubation in goat anti-mouse-HRP Ab (1:2500, Santa
Cruz Biotechnology, Santa Cruz, CA, USA). After three more
washes, blots were processed and signals were visualised using
enhanced chemiluminescence (Amersham Biosciences, Little
Chalfont Buckinghamshire, England).
For detection of activated extracellular signal-regulated kinase
(ERK), cells in complete medium were washed in ice-cold TBS and
lysed in standard radioimmunoprecipitation assay buffer with
phosphatase inhibitors (TBS, 0.1% SDS, 0.5% sodium deoxycho-
late, 1% Triton X-100, 10mM sodium pyrophosphate, 25mM
b-glycerophosphate, 1mM, sodium orthovanadate, 25mM sodium
fluoride). Forty microlitres of precleared lysate were then analysed
by Western blot using the anti-phospho-ERK1/2 and anti-total
ERK1/2 Abs obtained from Cell Signaling Technology (Beverly,
MA, USA).
Soft agar assay
A total of 1 10
5 cells of parental, PI and cured cells were mixed
(1:1) in 2 RPMI containing 10% FBS and 1.2% low-melting
temperature agarose (SeaPlaque, Rockland, ME, USA) and allowed
to grow for 4 weeks. Colonies were then fixed in ethanol/acetic acid
overnight and stained with Coomassie brilliant blue. Photomicro-
graphs of the wells were taken on a Kodak DC290 ZOOM digital
camera.
Reovirus infection of the Raji cell lines in vitro
One million cells of each cell line were dispensed into 24-well
plates and infected with reovirus or ISVPs at an MOI of
20PFUcell
 1. For experiments involving the use of proteases,
infection with reovirus was carried out in the presence of
10mgml
 1 TLCK-treated chymotrypsin (replaced every 24h for
up to 96h). For E64 protease inhibitor (Sigma) treatment in vitro,
cells were exposed to 50mM of E64 in PBS 1h before reovirus
infection. Virus was allowed to bind for 45min at 41C, after which
E64 was again added to the cells to a final concentration of 50mM.
WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazo-
lio]-1,3-benzene disulphonate) assays (Roche, Diagnostics, Laval,
Qc, Canada) were used to measure cell viability. Cells were infected
as above and a tetrazolium salt WST-1 was added to the cultures
for 6h before the 96h time point postinfection. The cleavage of
WST-1 to formazan by metabolically active cells was quantified by
scanning the plates at 450nm reference wavelength in a microtitre
plate reader. Medium without WST-1 was used as background
control. The experiments were performed in triplicate.
For metabolic labelling, [
35S]methionine was added to the
culture medium at designated times for a period of 6h. Cells were
harvested and lysed in lysis buffer (PBS) containing 1% Triton
X-100, 0.5% sodium deoxycholate and 1mM EDTA). Lysates were
cleared of debris by centrifugation and supernatants were stored at
 701C until use. Polyclonal rabbit anti-reovirus serotype 3 serum
was used for immunoprecipitation of [
35S]methionine-labelled
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et al, 1981). Immunoprecipitated proteins were subjected to SDS–
PAGE (Laemmli, 1970) followed by autoradiography.
Progeny virus production
Three million cells grown in six-well plates were infected with
reovirus at an MOI of 20. At 96h postinfection, the plates were
frozen and stored at  701C until use. To assay for progeny virus
production, the plates were subjected to three rounds of freeze–
thaw, and the supernatants were used for plaque titration on L929
cells. All titration experiments were repeated in triplicate.
SCID mice studies
Six- to 8-week-old Fox-Chase SCID mice were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA). The animals were
maintained under specific pathogen-free conditions and according
to a protocol approved by the University of Calgary Animal Care
Committee. As a xenograft model, 1.0 10
7 Raji or Raji-derived
cells (PI or Cured) were injected subcutaneously in the hind flank
of the mice. Once palpable tumours were established (day 0),
1.0 10
7PFU of live reovirus in PBS was administered intratumo-
rally (experimental group), or PBS alone (control group). Two-
dimensional tumour measurements were performed with calipers
every other day for 25 days or until the animals showed severe
morbidity due to excess tumour burden or complications due to
viral infection.
In vivo experiments involving the use of the protease inhibitor
E64 were similarly carried out, with the exception that 1mg of E64
in PBS was injected IP into the mouse and subsequently every
second day, until day 8 for the E64 alone and the E64þreovirus
group. This concentration was chosen from a previous report
showing the inactivation of proteases by E64 in vivo without
affecting the tumour growth of a Burkitt lymphoma tumour (Sebti
et al, 1991). For the E64þreovirus group, E64 injection was
performed 1h before the single reovirus injection. For ISVP
treatment, ISVPs were prepared as described above and
1.0 10
7PFUs were administered once intratumorally.
Histology and immunohistochemistry
Tumours (or remaining masses) taken from animals on day 20
post-intratumoral reovirus (or saline) injection were fixed in 10%
neutral-buffered formalin and embedded in paraffin for histolo-
gical analysis. Sections were then immersed in xylene, followed by
rehydration in decreasing concentrations of ethanol. For histo-
pathological examination, the sections were stained with haema-
toxylin and eosin (H&E). For immunohistochemistry, endogenous
peroxidase was inactivated in 3% hydrogen peroxide in methanol
for 15min. Sections were then incubated with a primary rabbit
anti-reovirus polyclonal antibody (1/1000 in PBS with 10% goat
serum and 0.1% Triton X-100) that was partially purified by
ammonium sulphate precipitation. Slides were washed in PBS and
then subjected to avidin–biotin–horseradish peroxidase staining
as recommended by the manufacturer (Vector, Burlingame, CA,
USA) and counter-stained in haematoxylin.
Statistical analysis
Statistical Analysis Software GraphPad Prism (version 4, GraphPad
Software Inc., San Diego, CA, USA) was used for statistical
analyses. Wilcoxon’s signed-rank tests were used to compare the
distributions of tumour sizes. All reported P-values were two-sided
and were considered to be statistically significant at o0.05.
RESULTS
Growth of PI, cured and parental Raji cells in vitro
To generate PI cells, parental Raji cells were subjected to multiple
rounds of infection by reovirus type 3 Dearing. Most cells were
killed by the virus, but a very small number of cells survived and
were propagated for the next several months. After undergoing two
crisis periods, a resistant population was established that was PI
and that continuously shed infectious viral particles into the
culture medium. These cells (designated Raji PI) could subse-
quently be cured of reovirus infection using anti-reovirus
antibodies. Cured cells (designated Raji cured) contained no
detectable viral proteins or RNA (see below). Evaluation of the
cluster of differentiation antigens present on PI and cured cells
verified their common origin from Raji cells (data not shown).
We first characterised and compared the Raji PI and Raji cured
cells to the parental Raji cells. RT–PCR and immunofluorescence
confirmed the presence of reovirus only in the PI cells (Figure 1A);
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Figure 1 Growth of the Raji parental, PI and cured cells. (A) The left
panel shows polymerase chain reaction of reovirus S1 and S2 mRNA
transcript in Raji parental, PI and cured cells. Equal amounts of RNA from
each sample were subjected to RT–PCR, followed by selective
amplification of reovirus S1 or S2 cDNA and GAPDH. The right panel
shows immunofluorescence of reovirus proteins expressed only in PI cells.
Cells grown under normal conditions were fixed, processed and reacted
with rabbit anti-reovirus type 3 antibody, followed by FITC-conjugated goat
anti-rabbit IgG and mounted with DAPI-stained mounting medium. The
magnification for all panels was  400. (B) Photomicrographs of the Raji
parental, PI and cured cells in culture and growth curves assessed by
staining the cells with 0.25% Trypan Blue. Viable (unstained) cells from
three independent wells were counted using a haemocytometer. (C) Ras
and ERK activity in Raji, PI and cured cells. (D) Growth of Raji parental, PI
and cured cells in soft agar. A total of 1 10
5 cells were mixed (1:1) in
2 RPMI containing 10% FBS and 1.2% low-melting temperature agarose
(SeaPlaque) and allowed to grow for 4 weeks. Colonies were then fixed,
stained with Coomassie brilliant blue and photomicrographed.
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Persistently infected cells also tended to form clusters in culture
and grew at a slightly slower rate while the proliferation rate of the
cured cells surpassed that of the parental cells (Figure 1B).
Examination of activated Ras-GTP and phosphorylated ERK1/2
levels revealed that both were significantly reduced in PI cells, but
were restored in the cured cells to those seen for the parental cells
(Figure 1C). Moreover, cured and parental Raji cells readily
formed colonies in soft agar, whereas PI cells did not (Figure 1D);
this suggests that the cured cells, like the parental cells, are likely
tumorigenic whereas the PI cells are likely nontumorigenic.
Parental and cured cells, but not PI cells, develop large
tumours in vivo
Despite numerous studies on reovirus PI cells, the tumorigenicity
of PI and cured cells has never been reported. Accordingly, the
cells were introduced subcutaneously into SCID mice, which had
previously been shown to support the growth of Raji tumours. The
results (Figure 2A) show that, in agreement with the in vitro soft
agar assay, both the parental and cured cells produced large
tumours, whereas Raji PI cells failed to grow in these mice.
Histological examination showed large and clearly proliferating
tumours in the Raji parental and Raji cured groups. The PI group
had small tumours that could not be palpated and were detectable
only microscopically by immunohistochemistry using anti-reo-
virus antibodies (Figure 2B). It is interesting to note that the
abilities of the three cell types to form tumours correlated with
their Ras-GTP and ERK1/2 levels.
Raji cured cells are resistant to reovirus oncolysis in vitro
but are susceptible in vivo
To determine the permissiveness of the Raji cured cells to reovirus
infection in vitro, the cells were infected with reovirus at an MOI of
20PFUcell
 1 and assessed for cytopathic effects, viability, viral
protein synthesis, and progeny virus production. As reported
previously, Raji parental cells became granular and irregular-
shaped, and manifested extensive cell clumping characteristic of
cytopathic effects following reovirus infection. Cured and PI cells
were however resistant to reovirus even at 96h postinfection.
Based on WST assay performed on the cells at this time point,
viability was reduced in the parental cell line to approximately
45%, whereas no change in viability was detected in the cured or PI
cells (Figure 3A).
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Figure 2 Tumorigenicity of Raji parental, PI and cured cells in SCID mice.
(A) SCID mice were subcutaneously implanted with 1 10
7 cells of Raji
parental, PI or cured cells. Tumour growth was followed for a period of
5 weeks and two-dimensional measurements were taken weekly with a
caliper. Resected tumours were photographed. (B) Haematoxylin and
eosin staining and IH of reovirus antigens in tumour tissue taken from Raji
parental, PI and cured tumours. Haematoxylin- and eosin-stained section
(original magnification  200) show large tumours 30 days postinjection in
the Raji and cured group. Tumours in the PI group were not apparent on
palpation and only small foci of tumour were found on histological
examination. Immunohistochemical of tumour sections (original magnifica-
tion  200) shows that only PI cells stain positively for reovirus proteins
(brown), although most of the tumour is necrotic.
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Figure 3 Effect of reovirus on Raji parental and cured cells in vitro.( A)
Cell viability. Raji parental, PI and cured cells were exposed to reovirus at an
MOI of 20PFUcell
 1, and viability at 96h postinfection was assessed using
WST-1 assay from three independent wells. Compared to controls,
P-values for reovirus-treated groups are Po0.001, P¼0.93 and P¼0.222
for Raji, Raji PI and Raji cured, respectively. (B) Viral protein synthesis.
Infected cells were metabolically labelled with [
35S]methionine for 6h at
42h postinfection. Cell lysates were prepared, and reovirus proteins were
immunoprecipitated with a polyclonal anti-reovirus antibody and analysed
by SDS–PAGE. The three size classes of reovirus proteins (l, m and s) are
indicated on the left. (C) Virus progeny. At 0 and 96h postinfection, cells
were harvested and freeze–thawed three times, and the virus titre in the
lysate was determined by plaque assay on L929 cells. Compared to input
virus, P-values for progeny virus at 96h postinfection are Po0.001,
P¼0.0015 and Po0.001. Error bars indicate s.e.m. from three separate
wells and *demonstrates statistical significance.
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sThe infected cells were also metabolically labelled with
[
35S]methionine, followed by immunoprecipitation with anti-
reovirus antibody for the detection of viral protein synthesis
(Figure 3B). The synthesis of the three viral protein groups
(l, m and s) was observed in the parental Raji cells, but not in the
Raji cured cells. Resistance of the cured cells to reovirus
infection was also evident from the lack of progeny virus
production even at 96h postinfection compared to the parental
cells (Figure 3C). As expected, the PI cells supported endogenous
viral protein synthesis, which did not appear to be enhanced
by the addition of exogenous reovirus (Figure 3B). The
continuous production of endogenous virus in PI cells was
accountable for the moderate enhancement in virus yield with
time (Figure 3C).
In view of the aggressiveness of the cured tumours and their
resistance to reovirus in vitro, we next assessed the susceptibility
of these cells to reovirus treatment in vivo. To this end, parental
and cured Raji lymphoma tumours grown subcutaneously in SCID
mice were subjected to a single intratumoral injection of
1 10
7PFUs of reovirus. We were surprised to find that, contrary
to their behaviour in vitro, Raji cured cells were now highly
susceptible to reovirus in vivo (Figure 4A). To determine if cell
death occurred by active viral infection, immunohistochemical
(IH) staining with anti-reovirus antibody was performed on
paraffin-embedded sections collected 24 days after reovirus
injection (Figure 4B). Haematoxylin/eosin staining confirmed the
killing of tumour cells in the live virus-treated group, and IH
staining with anti-reovirus antibody showed the presence of viral
proteins in the residual tumour cells of both Raji parental and Raji
cured cells. Therefore, cured cells that are resistant to reovirus in
vitro become susceptible to reovirus in vivo.
Cured cells are susceptible to in vitro infection by
protease-stripped virions
Based on current information on reovirus infection strategy, we
speculated that the discrepancy between the in vitro and in vivo
data could be due to the proteolytic microenvironment within
tumours that enhanced reovirus infection of the cured tumours by
converting reovirions into ISVPs. Such ISVPs have been shown to
be capable of infecting many restrictive cells that have somehow
lost their ability to process the uncoating of the incoming virion
(Dermody et al, 1993; Baer and Dermody, 1997; Wetzel et al, 1997;
Baer et al, 1999; Golden et al, 2002).
To test this idea, we first determined if resistance of the
cured cells to reovirus killing in vitro could be reversed by the
inclusion of a protease during infection with intact reovirions or
by using protease-stripped virions (ISVPs) directly. The
results (Figure 5A) show that there was a significant increase in
cell death when infection by reovirions was carried out in the
presence of chymotrypsin, or when ISVPs were used instead of
reovirions. Infected cells were also labelled with [
35S]methionine,
followed by immunoprecipitation with anti-reovirus antibody
for the detection of viral protein synthesis (Figure 5B). A drastic
increase in synthesis of the three viral protein groups l, m and s,
was evident in the Raji cured cells following infection with
reovirions in the presence of chymotrypsin or with ISVPs
alone. WST-1 assay confirmed the loss in viability of the cured
cells from these treatments (Figure 5C). These results clearly
show that the resistance of the cured cells to infection with
reovirus can be overcome by proteolytic processing of reovirus
into ISVP.
Protease inhibitor E64 prevents reovirus oncolysis in vitro
and in vivo
To see if a similar protease processing of virions occurs within Raji
cured tumours, which results in their susceptibility to killing by
reovirions in vivo, we used the specific cysteine protease inhibitor
E64, which has been shown to block the conversion of reovirions
to ISVPs (Baer and Dermody, 1997; Chandran and Nibert, 1998).
We first tested the effect of E64 on Raji and Raji cured cells in
vitro. The results (Figure 6A) show that E64 effectively blocked
infection of the Raji cells by reovirus but not by ISVPs. Raji cured
cells were once again only efficiently infected by ISVP and in the
presence of E64 as well.
If indeed a proteolytic environment in tumours is important
for reovirus permissiveness in vivo, as it is for cells in vitro,
treating mice bearing tumours with a protease inhibitor should
also impair reovirus oncolysis in vivo. To test this, mice
bearing subcutaneous Raji tumours were injected intraperitoneally
(i.p.) with E64 before a single intratumoral reovirus injection. I.p.
administration of E64 was continued every 2 days until day 8. As
observed above, reovirus treatment alone effectively prevented
tumour progression; however, reovirus therapy was rendered
ineffective in E64-treated mice (Figure 6B). Furthermore,
upon termination of the E64 treatment (at day 8), the tumours
were seen to regress. These results suggest that the microenviron-
ment inside the cured tumours is proteolytic, and such a
proteolytic environment promotes the conversion of reovirions
to ISVPs, which can then infect and kill the cured tumour cells that
have been selected for their resistance to infection by intact
virions.
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Figure 4 Effect of reovirus on parental and cured Raji tumours in vivo.
(A) Intratumoral reovirus therapy of lymphoid tumours in SCID mice.
SCID mice were subcutaneously implanted with 1 10
7 cells of either Raji
parental or cured cells. Following palpable tumour establishment, the
tumours received (on day 0) a single intratumoral injection of 1 10
7 PFUs
of live reovirus (n¼8) or saline control (n¼7). Tumour growth was
followed for a period of 25 days and measured two-dimensionally with a
caliper. *Differences are statistically significant with Po0.001 for
Rajiþreovirus and P¼0.002 for Raji curedþreovirus compared to
respective controls. (B) Haematoxylin and eosin staining and IH of
reovirus antigens in Raji parental and cured tumours after intratumoral
reovirus treatment. Haematoxylin- and eosin-stained section shows
necrosis of tumour cells 24 days after live reovirus treatment. IH-stained
section (original magnification  100 (left) and  200 (right)) of remaining
tumour cells stains positively for reovirus proteins (brown). Histological
examination of saline-treated (control) Raji and cured tumours showed
very large actively proliferating tumours (data not shown).
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Resistance to reovirus oncolysis is a phenomenon previously only
known to occur in vitro for a variety of cell types. This occurs
through the acquisition of a PI or cured cellular state (Taber et al,
1976; Ahmed et al, 1981; Ahmed and Fields, 1982; Danis et al, 1993;
Dermody et al, 1993, 1995; Baer and Dermody, 1997; Wetzel et al,
1997; Chappell et al, 1998; Baer et al, 1999; Ebert et al, 2004). The
aim of this study was to evaluate the potential limitations that the
emergence of PI or cured cells may pose for reovirus oncolytic
therapy. To assess this, we investigated the tumorigenicity and
subsequent susceptibility to reovirus of a PI Burkitt lymphoma cell
line (Raji) and its respective cured and parental counterparts. Our
data suggest that these two cellular states are not likely to be a
significant barrier to reovirus oncolysis clinically for two reasons:
(1) PI Raji cells were not tumorigenic in SCID mice, and (2) while
cured Raji cells readily form tumours, they were efficiently
eliminated by a single injection of reovirus despite their complete
resistance to oncolysis in vitro. This latter observation indicates
that reovirus’ oncolytic properties may be enhanced in vivo and
that in vitro testing of cell lines may not predict in vivo
susceptibility.
Reovirus is known to produce a persistent infection in a wide
range of cell lines including cancer cells (Ahmed et al, 1981;
Ahmed and Fields, 1982; Dermody et al, 1993; Dermody, 1998).
Despite this well-described cellular state, this is the first report
examining the tumorigenicity of reovirus PI or cured cancer cells.
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Figure 5 Infection of Raji cured cells by ISVP, or by reovirions in the
presence of chymotrypsin. (A) Cytopathic effects. Raji parental or cured
cells were exposed to ISVP, reovirus or reovirus in the presence of
chymotrypsin (CHT) at an MOI of 20PFUcell
 1, and photomicrographs
were taken at 72h postinfection. Original magnification  400. (B)
Reovirus protein synthesis in infected Raji parental and cured cells. Cells
were infected with ISVP, reovirus or reovirus in the presence of CHT, and
pulse-labelled with [
35S]methionine for 6h at 18h postinfection. The cells
were then harvested and lysed, and reovirus proteins were immunopre-
cipitated from an aliquot of the lysate using a rabbit polyclonal anti-reovirus
antibody, followed by SDS–PAGE. The three size classes of reovirus
proteins (l, m and s) are indicated on the left. (C) Viability of Raji parental
and cured cells infected with ISVP, reovirus or reovirus in the presence of
CHT. WST-1 assay was carried out on cells from three independent wells
at 96h postinfection. P-values compared with respective uninfected
controls are: Left panel, P¼0.012 (RajiþReo), P¼0.017 (RajiþISVP),
P¼0.61 (Raji curedþReo) and P¼0.026 (Raji curedþISVP). Right panel,
P¼0.019 (RajiþReo), Po0.001 (RajiþReoþCHT), P¼0.98 (Raji
curedþReo) and P¼0.0013 (Raji curedþReoþCHT). *Indicates
statistical significance.
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Figure 6 Infection of Raji and Raji cured cells in the presence of E64. (A)
Reovirus protein synthesis in infected Raji parental and cured cells treated
with E64. Cells were infected with ISVP or reovirus in the presence or
absence of E64, and pulse-labelled with [
35S]methionine for 6h at 18h
postinfection. The cells were then harvested and lysed, and reovirus
proteins were immunoprecipitated from an aliquot of the lysate using a
rabbit polyclonal anti-reovirus antibody, followed by SDS–PAGE. The
three size classes of reovirus proteins (l, m and s) are indicated on the left.
(B) Intratumoral reovirus therapy of lymphoid tumours in SCID mice
exposed to E64 injected i.p. SCID mice were subcutaneously implanted
with 1 10
7 cells of Raji parental cells. Following palpable tumour
establishment, the tumours received (on day 0) either 1mg per mouse
of E64 in PBS alone (n¼5) or 1h before a single intratumoral injection of
1 10
7 PFUs of live reovirus (n¼5) and E64 was re-injected subsequently
every second day until day 8. E64 treatments were compared to PBS
control and reovirus alone group (n¼5). Tumour growth was followed for
a period of 12 days and measured two-dimensionally with a caliper.
*Wilcoxon’s signed-rank test (P¼0.0379) comparing tumour sizes of
reovirusþE64-treated group to reovirus-alone group.
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tumorigenicity upon clearance of the virus suggests that these PI
cells have never lost their intrinsic tumorigenic potential. Rather,
this potential is somehow suppressed by the presence of the
resident virus. In this regard, it is interesting to note that reovirus
PI 3T3 cells reportedly exhibited a decrease of 70–90% in the
number of the epidermal growth factor (EGF) receptors and a
corresponding decrease in EGF-stimulated DNA synthesis (Verdin
et al, 1986). Similarly, we observed a marked reduction of activated
Ras-GTP and phosphorylated ERK1/2 kinases in the PI cells when
compared to parental and cured cells. Reduced expression or
activation of important oncogenes and/or growth factors due to
the chronic presence of viral proteins and/or transcripts may
explain why these cells fail to colonise in soft agar and to form
tumours in mice. It is also noteworthy that persistent infection of
cancer lines by other oncolytic viruses, such as vesicular stomatis
virus (VSV), measles, adenovirus or herpesvirus, also occurs
(Minato et al, 1979; Wolfson et al, 1991; Flomenberg et al, 1996;
Kao et al, 1999), and that measles and VSV PI cells were reportedly
incapable of forming tumours in vivo (Minato et al, 1979;
Schattner et al, 1985). Similar to the reovirus PI cells reported
by Verdin et al, measles PI neuroblastoma cells showed a markedly
depressed level of H-Ras expression, which correlated with the loss
of malignant phenotypes (Wolfson et al, 1991). Whether these cells
can regain their tumorigenicity upon viral clearance is unknown at
present.
Our studies on the Raji cured cells have led us to suggest that
proteases present within these tumours are responsible for the
enhanced reovirus infection in vivo, since these cells are only
efficiently infected in vitro when reovirus is first proteolytically
processed into ISVP before infection. Indeed, addition of
exogenous proteases to the culture medium has been shown to
facilitate reovirus infection of a variety of cells, which would not
otherwise be susceptible (Golden et al, 2002). Studies have shown
that protease-generated ISVPs are capable of directly penetrating
the cell membrane and entering the cytoplasm where viral
replication can take place (Borsa et al, 1979; Chandran et al,
2002). Such a scenario probably plays out in the human
gastrointestinal tract where the presence of intestinal proteases
likely promotes reovirus infection. It is noteworthy that proteolytic
conversion of reovirions into ISVPs in the intestinal lumen has
been shown to be essential for efficient reovirus infection in mice
(Amerongen et al, 1994), and inhibitors of luminal serine proteases
reduce viral infectivity (Bass et al, 1990). Inhibitors of endosomal
and lysosomal proteases have been shown to restrict reovirus
infection in cell culture (Dermody et al, 1993; Baer and Dermody,
1997; Wetzel et al, 1997; Chandran and Nibert, 1998; Baer et al,
1999). In this study, we observed that addition of the protease
inhibitor E64 blocks reovirus oncolysis of Raji cells in vitro but
importantly also impairs Raji tumour regression in vivo, suggest-
ing the importance of proteases in reovirus oncolysis. Since high
levels of protease activity are known to exist in the microenviron-
ment of many tumours, particularly at the tumour–stroma
interface, and increased protease production occurs in a variety
of transformed cells (Rubin, 2003), tumours present an ideal
environment for reovirus replication. Furthermore, cells trans-
formed with oncogenic Ras have increased expression of proteases
(Chambers et al, 1992), and we have shown that reovirus
selectively infects cells with an activated Ras pathway (Coffey
et al, 1998; Strong et al, 1998). Collectively, our data suggest that
the proteolytic environment in tumours probably facilitates
reovirus uncoating, and this could account for its enhanced
oncolytic capability in vivo.
In view of the reovirus clinical trials currently underway, results
from this study should alleviate some concerns regarding the
potential problems with the tumorigenic potential of PI tumour
cells, as well as with the resistance of the cured tumour cells to
reovirus therapy. These results further suggest that reovirus could
have broadened oncolytic capabilities due to enhanced proteolytic
processing of virions within tumours, and that in vitro testing of
cancer cells or tumour specimens does not necessarily predict
which tumours will be resistant to reovirus infection in vivo.
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